TNFSF11 : Osteoprotegerin Inhibitor Screening ELISA Kit

背景（Background）

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production. This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

应用说明（Application）

This kit is developed for screening for inhibitors of human TNFSF11 binding to human Osteoprotegerin.

It is for research use only.

重构方法（Reconstitution）

Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.

存储（Storage）

Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

原理（Assay Principles）

This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new TNFSF11 pathway inhibitors. The assay takes advantage of our in house-developed binding of human Osteoprotegerin to immobilized human TNFSF11 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Osteoprotegerin, a human TNFSF11 protein, an anti-TNFSF11 neutralizing antibody (as method verified Std.).

Your experiment will include 4 simple steps:

a) Coat the plate with human TNFSF11.

b) Add your molecule of interest to the tests.

c) Add human Osteoprotegerin to bind the coated TNFSF11.

d) Add TMB or other colorimetric HRP substrate.

Finally, the half maximal inhibitory concentration (IC50) of your compound to TNFSF11: Osteoprotegerin binding will be determined by comparing OD readings among different experimental groups.